Mevacor

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mevacor

Quick Facts: Mevacor (Lovastatin)

Property Description
Active ingredient Lovastatin
Form Oral Tablet (Immediate and Extended-Release)
Pharmacological Class HMG-CoA Reductase Inhibitor (Statin)
General Purpose Antihyperlipidemic / Cardiovascular Risk Reduction
Origin Semi-synthetic (originally derived from Aspergillus terreus fermentation)

What Type of Medication is Mevacor (Lovastatin)?

Mevacor is a prescription-only medication containing the active component Lovastatin, which is classified within the group of medicines known as HMG-CoA Reductase Inhibitors, commonly referred to as statins. This pharmacological classification identifies the drug as a foundational agent used for managing abnormal lipid levels.

Lovastatin was the first specific inhibitor of HMG-CoA reductase to receive clinical approval for this therapeutic use. This drug belongs to a class of compounds used for lowering the concentration of fats and cholesterol in the bloodstream. Mevacor is a single-ingredient product typically taken through the oral route as a tablet.


Composition, Form, and Origin

The medication's active substance is Lovastatin, which is administered as an inactive \gamma -lactone pro-drug that requires processing by the liver to be converted into its pharmacologically active \beta -hydroxy acid form. This requirement for hepatic conversion is a distinguishing chemical factor compared to statins that are biologically active upon ingestion.

Lovastatin has a semi-synthetic origin; it was initially isolated from the fermentation products of the fungus Aspergillus terreus. This natural precursor provides the molecular structure that enables it to interfere with the body's internal cholesterol synthesis pathway. The final product is delivered in the solid form of an oral tablet.


General Therapeutic Purpose

The overall therapeutic purpose of Mevacor is to function as an antihyperlipidemic agent, targeting and improving the balance of fats in the blood, such as in cases of dyslipidemia. The drug works by competitively inhibiting the enzyme HMG-CoA reductase, which is a key step in the liver's production of cholesterol.

By slowing this production, Mevacor decreases the concentration of Low-Density Lipoprotein Cholesterol (LDL-C), often called "bad cholesterol," in the circulation. The general benefit of consistently lowering LDL-C levels is its contribution to cardiovascular risk reduction, helping to limit the progressive buildup of atherosclerotic plaque in arterial walls. Lovastatin is utilized for its efficacy in managing elevated cholesterol levels. This type of medication is used as part of an overall strategy to manage high cholesterol and reduce the risk of heart disease.

Regulatory References

  1. NIH: Lovastatin Pharmacokinetics/Prodrug Conversion

What side effects are possible with Mevacor?

Possible Side Effects and Safety Information

The official safety profile for Mevacor (Lovastatin) is structured by governmental regulatory authorities to classify and communicate documented risks, which are primarily centered on the musculoskeletal and hepatic systems.

Adverse Reaction Scope

Category Documented Entity / Classification
Common Side Effects Infection, headache, accidental injury, flatulence, abdominal pain, diarrhea, and constipation.
System-Organ Classes Musculoskeletal and Connective Tissue Disorders; Hepato-biliary Disorders; Gastrointestinal Disorders; Nervous System Disorders.
Serious Adverse Reactions Rhabdomyolysis (severe muscle breakdown potentially leading to acute renal failure) and rare reports of Fatal and Non-fatal Hepatic Failure and Immune-Mediated Necrotizing Myopathy (IMNM).
Population Constraints The drug is contraindicated for women who are pregnant or nursing due to the potential for fetal or infant harm. Advanced age (ge 65 years) and severe renal impairment are listed as predisposing factors for myopathy.

Safety-Related Restrictions

The use of Lovastatin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels. The risk of serious muscle effects, including rhabdomyolysis, increases in a dose-dependent manner and is significantly heightened when co-administered with strong CYP3A4 inhibitors (e.g., certain antifungals or HIV protease inhibitors), requiring dosage limitations or avoidance as specified in the official label. Therapy may also require temporary withholding during acute, serious conditions such as sepsis or major trauma.

Connection to the Overall Safety Profile

Regulatory documentation confirms that while many adverse reactions are common and mild, the most significant risks are rare, potentially severe effects on the muscles and liver. These risks are formally categorized to highlight predisposing factors and drug interactions, which collectively define the safety limitations and constraints for its use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents specify the profile and necessary emergency actions for a suspected Mevacor (lovastatin) overdose. Based on human reports, single ingestions of large amounts may not present with specific symptoms, and affected patients have typically recovered without complication. However, severe overdose carries a risk for serious physiological events.

The most critical documented manifestations of high exposure involve the musculoskeletal system, including myopathy and its severe form, rhabdomyolysis (skeletal muscle breakdown). Rhabdomyolysis can potentially lead to acute renal failure. Other potential findings include elevated liver function tests (LFTs) and peripheral neuropathy. Patients with severe renal impairment or advanced age are considered to have an increased risk profile for these complications.

If an overdose is suspected, immediate medical attention must be sought. It is required to contact a Poison Control Center right away. Urgent emergency help is necessary if the person collapses, has trouble breathing, or has a seizure. According to regulatory information, no specific antidote is known for lovastatin overdose. Management is therefore restricted to symptomatic and supportive treatment provided in a medical setting, focusing on maintaining vital functions and monitoring for the development of severe complications.

Therapeutic Uses of Mevacor

Mevacor (Lovastatin) is prescribed to manage high blood lipid levels and reduce the corresponding risk of serious cardiovascular disease. The medication is used as part of a therapeutic strategy and is applicable for conditions such as primary hypercholesterolemia, mixed dyslipidemia, and heterozygous familial hypercholesterolemia.


Applied in Addressing Systemic Imbalance (Lipid Management)

Mevacor is commonly used to help with managing conditions characterized by elevated blood lipid levels, specifically high Low-Density Lipoprotein Cholesterol (LDL-C) and triglycerides. It is applied across domains where additional supportive management is appropriate for patients facing this systemic imbalance. The medication may assist with managing these systemic factors, which are linked to increased physiological stress.


Supports Patients in Maintaining Functional Stability (Risk Mitigation)

The medication is relevant for easing the overall risk of major cardiovascular events, such as a heart attack or stroke, in individuals with high cholesterol or established heart disease. This supports general well-being during periods of asymptomatic risk by assisting with managing the primary cause.


Quick Fact: Support for Cardiovascular Health

Domain Therapeutic Benefit
Systemic Imbalance Assists with lowering elevated LDL-C and triglyceride concentrations.
Risk Mitigation Plays a role in managing the overall risk of major cardiovascular events.
Specific Population Relevant for managing elevated lipids in adolescents with Familial Hypercholesterolemia.

Eligibility and Restrictions for Use

Mevacor (lovastatin) eligibility is defined by strict regulatory criteria concerning a patient’s health status and age, as documented in official prescribing information.

Contraindicated Populations (Must Not Use)

The medicine is contraindicated for patients with active liver disease, including unexplained, persistent elevations in hepatic transaminase levels. Use is also contraindicated for women who are pregnant or may become pregnant, and for nursing mothers (lactation). Individuals with a known hypersensitivity to any component are also ineligible.

Age-Based Eligibility

Population Regulatory Eligibility Status
Adults Approved for use with high cholesterol.
Adolescents (10–17 yrs) Permitted only for patients with Heterozygous Familial Hypercholesterolemia (HeFH).
Children (<10 yrs) Safety and effectiveness are not established.

Eligibility-Related Restrictions

Use is restricted and requires careful consideration in patients with severe renal impairment (creatinine clearance <30 mL/min). The medicine is advised to be temporarily discontinued in the event of acute systemic illnesses or major surgical procedures. Advanced age (65 years) is also cited as a factor requiring clinical caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Mevacor (lovastatin) can interact with various other medicines and products, primarily by affecting the levels of lovastatin in the body. This is crucial because lovastatin is metabolized by the enzyme Cytochrome P450 3A4 (CYP3A4).

Contraindicated Combinations

Concomitant use of lovastatin is contraindicated with medicines that are strong inhibitors of the CYP3A4 enzyme. This combination significantly raises the blood concentration of lovastatin, substantially increasing the risk of muscle injury (myopathy/rhabdomyolysis).

Interacting medicines in this category include:

  • Certain antifungals (e.g., itraconazole, ketoconazole, posaconazole)
  • Certain macrolide antibiotics (e.g., erythromycin, clarithromycin, telithromycin)
  • HIV protease inhibitors (e.g., ritonavir, atazanavir)
  • The antidepressant nefazodone

Combinations Requiring Dose Limits

To manage the risk of elevated lovastatin exposure and associated muscle injury, specific dose restrictions are required when lovastatin is used with other medicines:

  • A maximum daily dose of 20 mg lovastatin is mandated with gemfibrozil, cyclosporine, danazol, or lipid-lowering doses of niacin (ge 1 g/day).
  • A maximum daily dose of 40 mg lovastatin is mandated with amiodarone or verapamil.

Other drugs, such as fibrates (e.g., fenofibrate), may increase the risk of muscle problems when combined with lovastatin. Additionally, the consumption of grapefruit juice should be avoided as it also inhibits CYP3A4, leading to increased lovastatin levels.

Mechanism of Action

Primary Blockade of Cholesterol Production

The inactive pro-drug Lovastatin is converted in the liver to its active beta-hydroxy acid metabolite. This active form works through competitive inhibition of the HMG-CoA Reductase enzyme, blocking the rate-limiting step in the Mevalonate pathway . This action reduces the synthesis of cholesterol within liver cells, which initiates the relevant downstream physiological cascades.


⬆️ Enhanced Clearance of Lipoprotein Particles

The resulting reduction in the liver's internal cholesterol pool triggers a cellular response to modulate internal cholesterol homeostasis. Liver cells compensate by upregulating the expression of Low-Density Lipoprotein (LDL) Receptors on their surface . This increase in receptor density enhances the rate at which LDL cholesterol particles are captured and removed from the plasma circulation, resulting in a systemic reduction in their concentration.


Secondary Modulation of Vascular Cell Signaling

The inhibition of the Mevalonate pathway also reduces the production of metabolic intermediates known as isoprenoids. By limiting these intermediates, the drug indirectly interferes with the prenylation of vascular signaling proteins like Rho and Rac. This non-lipid-related effect is a pleiotropic mechanism that modulates endothelial function and influences inflammatory markers within the arteries.

Dosage and Administration Information

How to Use Mevacor (Lovastatin): Official Administration Guidelines

Lovastatin is administered via the oral route as a tablet and is intended for long-term use as part of a chronic management plan. The specific instructions for administration, dosing, and timing are dependent on the tablet formulation, which includes both immediate-release (IR) and extended-release (ER) forms.


Standard Dosing and Administration

The standard adult dosing regimen begins with an initial dose typically set at 20 mg once daily. Dosage adjustments are made at intervals of 4 weeks or longer until the desired response is achieved. The total maintenance dose for the immediate-release tablet can range from 10 mg up to a maximum of 80 mg per day, which may be taken as a single dose or in two divided doses. The maximum daily dose for the extended-release tablet is 60 mg.

Timing and Food Requirement:

  • Immediate-Release (IR) tablets must be taken with the evening meal.
  • Extended-Release (ER) tablets are taken in the evening, generally at bedtime.

Special Procedural and Population Rules

Official instructions provide specific guidance for certain patient populations and administration constraints:

  • Tablet Handling: Extended-release tablets must be swallowed whole and should not be crushed, broken, or chewed.
  • Pediatric Dosing: For patients aged 10 to 17 years with Heterozygous Familial Hypercholesterolemia (HeFH), the dose is limited to a range of 10 mg to a maximum of 40 mg per day.
  • Renal Impairment: For patients with severe kidney impairment (CrCL < 30 mL/min), increasing the dosage above 20 mg per day must be done with caution.
  • Missed Dose: If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose, in which case the missed dose should be skipped; doses must not be doubled.

Recent Clinical Evidence

Clinical Evidence Summary

Mevacor (lovastatin) belongs to the statin class of medications, which are studied primarily for their role in lowering levels of low-density lipoprotein cholesterol (LDL-C). Research related to lovastatin has contributed significantly to the understanding of lipid management for cardiovascular health.

Evidence from major clinical trials supports the use of lovastatin in both primary and secondary prevention efforts. Primary prevention studies have focused on individuals who have not yet had a major cardiovascular event, but who may have risk factors such as moderately elevated cholesterol and below-average high-density lipoprotein cholesterol (HDL-C) levels. In these cohorts, lovastatin was observed to result in reductions in the incidence of a first major coronary event.

Impact on Cardiovascular Outcomes

Lovastatin has also been investigated for secondary prevention, involving patients with established coronary heart disease (CHD). Findings from studies involving lovastatin or other statins in this class indicate that lowering LDL-C is associated with a reduction in the risk of recurrent events, such as non-fatal myocardial infarction and the need for coronary revascularization procedures. These studies generally reported a dose-dependent reduction in LDL-C and, over long-term follow-up (e.g., several years), an observed effect on the progression of atherosclerosis in the carotid arteries, as measured by changes in the intimal-medial thickness.

Lipid Profile Changes

Clinical data consistently show that lovastatin can produce favorable changes in the overall lipid profile. Common observations across various studies include:

Lipid Parameter Observed Change
LDL Cholesterol (LDL-C) Significant reduction
Total Cholesterol (TC) Reduction
HDL Cholesterol (HDL-C) Modest increase
Triglycerides Reduction

These results underpin the medication's therapeutic role in dyslipidemia management, a core element of reducing cardiovascular risk.

Frequently Asked Questions (FAQ)

Common questions about Mevacor (FAQ)


Q: Are the muscle aches and pains I've heard about common with Mevacor use?

According to official product information, muscle aches and pains (medically known as myalgia) are among the commonly reported side effects. While most muscle discomfort is mild, official documentation describes a full spectrum of muscle issues, including the rare, serious condition known as rhabdomyolysis. It is important to distinguish between common discomfort and signs of a more serious issue.


Q: I heard Mevacor can cause memory issues—is this documented in official sources?

Regulatory documents have noted post-marketing reports of cognitive impairment among some users of statins, including Mevacor. These effects can include memory loss, forgetfulness, or confusion. Official sources generally describe these reports as non-serious and usually reversible once the medication is stopped.


Q: How long does it usually take for Mevacor to show an effect on cholesterol levels?

Studies show that a noticeable therapeutic response in cholesterol levels is often observed within the first two weeks of starting treatment. The maximum therapeutic effect of Mevacor typically takes between four to six weeks to be achieved. This documented timeframe informs the monitoring period used by healthcare providers when assessing treatment.


Q: Is it necessary to take Mevacor indefinitely once treatment is started?

Mevacor is prescribed as part of a long-term plan for managing chronic high cholesterol and reducing cardiovascular risk over time. The necessity for continued treatment is not guaranteed to be indefinite, as it depends on an individual's response and whether their therapeutic goals are met. Official information describes its role in a long-term chronic management plan.


Q: Is Mevacor generally considered appropriate for elderly patients, based on research?

Official prescribing information notes that advanced age (defined as 65 years and older) is cited as a predisposing factor that increases the risk of muscle injury (myopathy). For this reason, official labels recommend mathbfclinical mathbfcaution and close observation. However, there is no mandate for dose adjustment based on age alone.


Q: Does Mevacor require regular blood tests beyond cholesterol checks?

Yes, beyond regular cholesterol checks, baseline mathbfliver mathbfenzyme mathbftests are typically required before starting Mevacor. While routine, scheduled monitoring of liver enzymes is no longer routinely recommended by official sources, testing may still be performed if a patient experiences symptoms that suggest a possible liver injury.


Q: Why do official sources sometimes mention taking Mevacor with food?

Official product information states that the mathbfimmediate-mathbfrelease tablets must be taken mathbfwith mathbffood, specifically the evening meal. This is a pharmacokinetic requirement because the amount of drug that the body absorbs (its bioavailability) is significantly mathbfreduced when the immediate-release tablet is taken on an empty stomach.


Q: Can Mevacor affect sleep patterns, according to reported data?

According to documented clinical data, trouble sleeping, medically known as mathbfinsomnia, is listed as a common side effect of lovastatin. This is included in the official safety profile for the medication.


Q: What common over-the-counter supplements might have known interactions with Mevacor?

Regulatory documents mention that certain supplements may interact with Mevacor. For example, mathbfSt. mathbfJohn's mathbfwort can lower the level of Mevacor in the body, which could make it less effective. Furthermore, official sources state that mathbfRed mathbfyeast mathbfrice is mathbfadvised mathbfagainst because it contains the same active ingredient as Mevacor, which increases the risk of side effects.


Q: How often are lipid panels (cholesterol checks) recommended when taking Mevacor?

Official monitoring guidelines recommend a mathbfbaseline lipid panel before starting treatment. The panel should then be checked again mathbf4 mathbfto mathbf12 mathbfweeks after initiating therapy or adjusting the dose. Following stabilization, regulatory guidelines suggest checking the lipid panel mathbfevery mathbf3 mathbfto mathbf12 mathbfmonths thereafter.


Q: How does Mevacor fit into a comprehensive treatment plan that includes diet and exercise?

Mevacor (lovastatin) is officially indicated as an mathbfadjunct mathbfto mathbfdiet and exercise. This means the medication is intended to support and enhance a healthy lifestyle, not replace it. Official guidance states that a mathbfstandard mathbfcholesterol-mathbflowering mathbfdiet is to be started before and continued during the entire treatment period.


Q: Are there official recommendations regarding Mevacor use and consumption of alcohol?

Official warnings state that the consumption of mathbfalcohol, or large amounts of it, is mathbfadvised mathbfagainst while taking Mevacor. Alcohol consumption may increase triglyceride levels and can also raise the mathbfrisk mathbfof mathbfliver mathbfdamage when combined with this medication.


Q: Are there official guidelines for patients who experience muscle discomfort while on Mevacor?

Official regulatory guidelines state that mathbfunexplained mathbfmuscle mathbfpain, tenderness, or weakness must be mathbfimmediately mathbfreported to a healthcare professional. These symptoms, particularly if accompanied by fever or dark urine, are noted as potential indicators of a more serious muscle condition.


Q: Why is Mevacor sometimes mentioned in discussions about changes in blood sugar?

Official FDA warnings state that statin medicines, including Mevacor, may lead to an mathbfincreased mathbfrisk mathbfof mathbfraised mathbfblood mathbfsugar mathbflevels. In some patients, this has been associated with the development of mathbfType mathbf2 mathbfdiabetes.


Q: Is there any guidance on Mevacor use for people who have certain thyroid conditions?

Official labeling identifies mathbfpoorly mathbfcontrolled mathbfhypothyroidism (an underactive thyroid) as a factor that mathbfincreases mathbfthe mathbfrisk of developing mathbfmuscle mathbfdamage (myopathy) while taking Mevacor. This highlights the importance of managing thyroid issues before and during treatment.


Q: Is it true that in some cases, aggressive lifestyle changes can make Mevacor unnecessary?

Mevacor is typically initiated only after other measures, such as a cholesterol-lowering mathbfdiet, mathbfexercise, and mathbfweight mathbfreduction, have been determined to be mathbfinadequate on their own. This reflects the medication's official role as a treatment component used when lifestyle modifications are not sufficient to achieve therapeutic goals.


Q: What is the half-life of Mevacor, according to documented pharmacokinetic information?

According to official pharmacokinetic information, the mathbfhalf-mathbflife of the active component of the drug (the beta-hydroxyacid metabolite) is documented at mathbf1.1 mathbfto mathbf1.7 mathbfhours. The half-life is the time required for the concentration of the substance in the body to be reduced by half.

How should Mevacor be stored and disposed of?

Storage and Disposal Conditions

Official regulatory documents define strict environmental and container requirements for storing Mevacor (lovastatin) tablets:

  • Storage Environment: The medication must be kept at room temperature and explicitly protected from excess heat, moisture, and direct light. It is mandatory to keep from freezing.
  • Container and Protection: The tablets must be stored in the original container, which must be kept tightly closed. The product must be stored out of the sight and reach of children, and safety caps must be locked.
  • Disposal: Unused or expired lovastatin must not be disposed of in wastewater or household garbage. Regulatory agencies recommend using a medicine take-back program or following specific governmental guidelines for proper home disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mevacor found in:

A-Z Index: